Affordable Cancer Drugs: What Impact Will New Limited Margins Have on Patients

In 2026, the Indian government imposed a capped margin of 25 % on the production and sale of oncology drugs, aiming to reduce drug costs for cancer patients. Under this policy, drug manufacturers and importers can earn only a 25 % profit, while the remaining cost can be used to recover expenses.

Industry representatives say that this step could lead to a 10‑15 % drop in drug prices, providing economic relief to more than 1.5 crore cancer patients.

However, pharmaceutical companies have warned that the margin cap could affect investment in research and development (R&D). They argue that high profits are essential for innovation, especially for the development of new drugs for rare cancers. If the margin is reduced further, companies may consider exiting the Indian market, which could limit drug availability.

Policymakers have introduced a formula to address this concern, which includes keeping drug prices controlled while incorporating a separate grant mechanism for R&D.

Public health experts believe that successful implementation of the policy will increase drug access as well as strengthen the availability of drugs in health‑insurance schemes and public hospitals. Patient organizations have urged the government to ensure, while dialoguing with drug companies, improvements in the drug distribution network alongside the margin cap. Under this initiative, despite lower drug prices, improvements in the supply chain and healthcare infrastructure are necessary to provide patients with timely treatment.